Canine von Willebrand Disease: Diagnosis and Management

At a Glance

Canine von Willebrand disease (vWD) is the most common inherited bleeding disorder in dogs, caused by a deficiency or dysfunction of von Willebrand factor (vWF), a protein essential for platelet adhesion and stabilization of factor VIII. The disease presents with mucosal bleeding, prolonged bleeding after surgery or trauma, and variable clinical severity depending on the type and degree of vWF deficiency. Diagnosis relies on measuring vWF antigen concentration (vWF:Ag), with buccal mucosal bleeding time (BMBT) as a supportive screening test. Management focuses on perioperative prophylaxis using cryoprecipitate or desmopressin (DDAVP), avoidance of drugs that impair platelet function, and careful surgical planning. Breed predispositions are well documented, with Doberman Pinschers, Scottish Terriers, and Shetland Sheepdogs among those at increased risk.

Understanding Canine von Willebrand Disease

Definition and Pathophysiology

von Willebrand disease in dogs is a hereditary hemorrhagic disorder resulting from deficiency or dysfunction of von Willebrand factor, a large multimeric glycoprotein that mediates platelet adhesion to exposed subendothelium at sites of vascular injury. vWF also serves as a carrier protein for coagulation factor VIII, protecting it from proteolytic degradation. The Merck Veterinary Manual provides comprehensive reference information on canine coagulation disorders and their clinical presentation (Merck Veterinary Manual, https://www.merckvetmanual.com/).

The pathophysiology of vWD involves impaired primary hemostasis. Without adequate functional vWF, platelets cannot adhere effectively to damaged blood vessel walls, leading to prolonged bleeding from mucosal surfaces, surgical sites, and traumatic wounds. The disease has been characterized in both dogs and cats, with the veterinary literature documenting its clinical features and management approaches (von Willebrand's disease in the dog and cat, The Veterinary clinics of North America. Small animal practice, 1996, https://pubmed.ncbi.nlm.nih.gov/8863392).

Classification of vWD Types

Canine vWD is classified into three major types based on the nature and severity of the vWF deficiency. Type 1 vWD is a partial quantitative deficiency, where vWF is present but at reduced levels. Type 2 vWD involves a qualitative defect, with abnormal vWF multimers that lack the high-molecular-weight forms most effective in platelet adhesion. Type 3 vWD represents a severe quantitative deficiency, with virtually undetectable vWF levels. This classification system parallels that used in human medicine and has been validated through research in animal models (Mouse models of von Willebrand disease, Journal of thrombosis and haemostasis : JTH, 2009, https://pubmed.ncbi.nlm.nih.gov/19630770).

Breed Predispositions

Breed-specific prevalence of vWD has been documented in multiple studies. The Doberman Pinscher is among the most commonly affected breeds, with a high carrier rate for Type 1 vWD. Scottish Terriers are predisposed to Type 3 vWD, the most severe form. Shetland Sheepdogs, German Shepherds, and German Shorthaired Pointers also show increased prevalence. A study examining the prevalence of von Willebrand disease in dogs from Sao Paulo State, Brazil, confirmed breed-associated patterns in a South American population (Prevalence of von Willebrand disease in dogs from Sao Paulo State, Brazil, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 2010, https://pubmed.ncbi.nlm.nih.gov/20093683). The ACVIM provides resources for veterinarians on genetic testing and breed-specific health screening (ACVIM, https://www.acvim.org/).

Clinical Presentation and History

Common Clinical Signs

Dogs with vWD typically present with signs of primary hemostatic failure. The most frequently observed clinical signs include epistaxis, gingival bleeding, prolonged bleeding from nail trims, hematuria, and excessive bleeding during estrus or after whelping. Petechiae and ecchymoses may be present but are less common than in thrombocytopenic disorders. Gastrointestinal bleeding can occur, manifesting as melena or hematochezia. The severity of clinical signs correlates with the type and degree of vWF deficiency, with Type 3 dogs showing the most pronounced bleeding tendencies.

Signalment and History Taking

A thorough history is essential when vWD is suspected. Key historical points include previous bleeding episodes after surgery, trauma, or routine procedures such as nail trimming or tooth brushing. A history of excessive bleeding in littermates, parents, or other related dogs supports a hereditary basis. Breed identification is critical, as certain breeds have well-documented predispositions. Age at first presentation varies, some dogs show signs during puppyhood, while others may not bleed excessively until challenged by surgery or trauma.

Differential Diagnoses

Other causes of primary hemostatic failure must be considered. Thrombocytopenia from immune-mediated disease, tick-borne infections, or bone marrow disorders can produce similar clinical signs. Thrombopathia, either inherited or acquired, may also cause mucosal bleeding. Acquired vWF deficiency has been reported in dogs with chronic liver disease, where impaired hepatic synthesis of vWF contributes to bleeding tendencies (Platelet function in dogs with chronic liver disease, The Journal of small animal practice, 2022, https://pubmed.ncbi.nlm.nih.gov/33900656). Coagulation factor deficiencies, such as hemophilia A or B, typically cause secondary hemostatic defects with joint bleeds and deep tissue hematomas instead of mucosal bleeding.

Diagnostic Approach

Initial Screening Tests

The initial evaluation of a dog with suspected vWD begins with a complete blood count (CBC) to assess platelet count and rule out thrombocytopenia. A normal platelet count in a dog with mucosal bleeding suggests a platelet function disorder or vWD. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are typically normal in vWD, as the coagulation cascade is intact. Severely affected Type 3 dogs may have a mildly prolonged aPTT due to reduced factor VIII stabilization by vWF.

Buccal Mucosal Bleeding Time

The buccal mucosal bleeding time (BMBT) is a practical in-clinic screening test for primary hemostatic function. The test involves making a standardized incision on the buccal mucosa and measuring the time until bleeding stops. Prolonged BMBT suggests impaired platelet adhesion, as seen in vWD, thrombocytopenia, or thrombopathia. The test has limitations, including operator dependence and variability with patient cooperation. A normal BMBT does not completely rule out mild vWD, but a prolonged BMBT in a dog with normal platelet count warrants specific vWF testing.

von Willebrand Factor Antigen Assay

The diagnostic test for vWD is measurement of plasma vWF antigen concentration (vWF:Ag). This quantitative immunoassay measures the amount of vWF protein present, regardless of its functional activity. Results are reported as a percentage of normal pooled canine plasma. Dogs with Type 1 vWD typically have vWF:Ag levels between 30% and 60% of normal. Type 3 dogs have levels below 1%. Type 2 vWD may show variable vWF:Ag levels, often in the 30-50% range, but with abnormal multimer distribution. The Merck Veterinary Manual provides reference ranges and interpretation guidelines for vWF:Ag testing (Merck Veterinary Manual, https://www.merckvetmanual.com/).

vWF Multimer Analysis

When Type 2 vWD is suspected based on discordance between vWF:Ag levels and clinical severity, vWF multimer analysis can be performed. This specialized test separates vWF multimers by size using gel electrophoresis. Normal plasma contains a full range of multimers, including high-molecular-weight forms. Type 2 vWD shows a relative deficiency of high-molecular-weight multimers, while Type 1 shows a uniform reduction across all multimer sizes. This test is available through specialized coagulation laboratories and is essential for accurate classification.

Genetic Testing

Genetic testing for vWD is available for several breeds with known mutations. The Doberman Pinscher mutation for Type 1 vWD is well characterized, and DNA testing can identify carrier and affected dogs. Scottish Terriers and Shetland Sheepdogs have breed-specific mutations for Type 3 vWD. Genetic testing is valuable for breeding decisions, as it allows identification of carriers before clinical signs develop. The ACVIM provides guidance on genetic testing protocols and interpretation (ACVIM, https://www.acvim.org/).

Practical Implementation Steps for Diagnosis

Step 1: Clinical Suspicion

Identify dogs with mucosal bleeding, prolonged bleeding after surgery or trauma, or a breed history of vWD. Record all bleeding episodes, including duration, severity, and inciting cause. Document any previous surgical procedures and bleeding complications. Note any medications that may affect platelet function, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.

Step 2: Initial Laboratory Evaluation

Perform a CBC to assess platelet count and rule out thrombocytopenia. Run PT and aPTT to evaluate secondary hemostasis. If platelet count is normal and coagulation times are normal, proceed with BMBT as a screening test. Record BMBT results in minutes and note any technical difficulties or patient factors that may affect interpretation.

Step 3: Specific vWF Testing

Submit a plasma sample for vWF:Ag assay. Collect blood into citrate tubes, centrifuge promptly, and separate plasma. Ship frozen plasma to a reference laboratory. Record the vWF:Ag result as a percentage of normal. If clinical suspicion is high but vWF:Ag is borderline normal, consider repeat testing or multimer analysis.

Step 4: Confirmatory and Genetic Testing

If vWF:Ag is low, classify the type based on severity and multimer analysis if available. For breeds with known mutations, perform genetic testing to confirm the specific mutation and determine carrier status. Record genetic test results and provide counseling on breeding implications.

Step 5: Documentation and Monitoring

Maintain a permanent record of all diagnostic results, including CBC, coagulation times, BMBT, vWF:Ag, and genetic test results. Update records with any new bleeding episodes or surgical procedures. For dogs diagnosed with vWD, provide a written summary for the owner and referring veterinarian.

Records and Measurements

Essential Diagnostic Records

Maintain a standardized record for each dog evaluated for vWD. Include signalment, breed, age, sex, and weight. Document all historical bleeding episodes with dates, duration, severity, and inciting causes. Record results of CBC, PT, aPTT, BMBT, and vWF:Ag assays. Note the laboratory performing each test and reference ranges used. For genetic tests, record the specific mutation tested and the result (clear, carrier, affected).

Bleeding Score System

A standardized bleeding score can help quantify clinical severity and track changes over time. Record the number and type of bleeding episodes in the past year. Score each episode for severity: mild (self-limiting, no intervention needed), moderate (requires veterinary attention but not transfusion), or severe (requires transfusion or hospitalization). Calculate a total bleeding score for comparison with vWF:Ag levels and to guide treatment decisions.

Perioperative Risk Assessment

For dogs undergoing surgery, create a perioperative risk assessment record. Include vWD type, vWF:Ag level, previous surgical bleeding history, planned procedure type, and anticipated blood loss. Document any prophylactic treatments administered, including DDAVP or cryoprecipitate, with doses, timing, and response. Record intraoperative bleeding assessment and postoperative monitoring for 72 hours.

Breeding Records

For breeding dogs, maintain genetic test results and pedigree information. Record the vWD status of both sire and dam. Document any bleeding episodes in offspring. Provide written recommendations for breeding management, including avoidance of carrier-to-carrier matings for Type 1 vWD and complete avoidance of breeding affected dogs for Type 3 vWD.

Treatment and Management Options

Perioperative Prophylaxis

The primary goal of perioperative management in dogs with vWD is to provide adequate hemostatic support to prevent excessive bleeding during and after surgery. The approach depends on the type and severity of vWD, the invasiveness of the procedure, and the dog's previous bleeding history. For Type 1 dogs with mild deficiency and low-risk procedures, no prophylaxis may be needed. For moderate to severe cases or high-risk surgeries, prophylactic treatment is indicated.

Cryoprecipitate

Cryoprecipitate is the treatment of choice for severe vWD or when DDAVP is ineffective. Cryoprecipitate is a plasma-derived blood product rich in vWF, factor VIII, and fibrinogen. It provides immediate replacement of functional vWF, supporting platelet adhesion and stabilizing factor VIII. Cryoprecipitate is administered intravenously, and the dose is based on the dog's weight and the severity of the deficiency. The product must be thawed and administered promptly after preparation. Cryoprecipitate carries a low risk of transfusion reactions but requires careful patient monitoring.

Desmopressin (DDAVP)

Desmopressin is a synthetic analog of antidiuretic hormone that stimulates release of stored vWF from endothelial cells. It is effective primarily in Type 1 vWD, where there is a partial quantitative deficiency but functional vWF is present in storage pools. DDAVP can be administered subcutaneously or intravenously, with peak vWF release occurring within 30 to 60 minutes. The response is variable and should be assessed by measuring vWF:Ag levels before and after administration. DDAVP is not effective in Type 3 vWD, where there is no stored vWF to release. Repeated doses within 24 to 48 hours may result in tachyphylaxis due to depletion of endothelial stores.

Fresh Frozen Plasma

Fresh frozen plasma (FFP) contains vWF and other coagulation factors and can be used when cryoprecipitate is unavailable. FFP requires larger volumes to achieve adequate vWF levels, increasing the risk of volume overload and transfusion reactions. FFP is a reasonable alternative for mild to moderate cases but is not preferred for severe vWD or major surgical procedures.

Avoidance of Antiplatelet Drugs

Dogs with vWD should avoid drugs that impair platelet function. NSAIDs, including carprofen, meloxicam, and aspirin, inhibit cyclooxygenase and reduce platelet aggregation. Corticosteroids may also affect platelet function. Other drugs to avoid include heparin, warfarin, and certain antibiotics such as penicillins and cephalosporins at high doses. Always review the medication history before surgery and discontinue antiplatelet drugs for an appropriate washout period when possible.

Common Failure Patterns

Failure to Diagnose Mild Cases

Mild Type 1 vWD is often underdiagnosed because affected dogs may not bleed excessively until challenged by surgery or trauma. A normal BMBT does not rule out mild vWD, and vWF:Ag testing should be performed in any dog with a suggestive history or breed predisposition. Failure to diagnose mild vWD can lead to unexpected surgical bleeding and complications.

Inadequate Perioperative Prophylaxis

Using DDAVP in Type 3 vWD, where it is ineffective, is a common management failure. Similarly, relying on FFP alone for severe cases may provide insufficient vWF levels. Always confirm the vWD type before selecting prophylactic treatment. For Type 2 and Type 3 vWD, cryoprecipitate is the preferred product.

Overreliance on BMBT

The BMBT is a screening test with significant limitations. Operator technique, patient movement, and mucosal thickness can affect results. A normal BMBT does not exclude vWD, and an abnormal BMBT does not confirm it. Always confirm with vWF:Ag testing before making a diagnosis.

Ignoring Breed-Specific Patterns

Breed-specific mutations and prevalence patterns are well documented. Failing to consider breed predisposition can delay diagnosis. For example, a Doberman Pinscher with mild bleeding should be tested for vWD even if the BMBT is normal. Similarly, a Scottish Terrier with severe bleeding should be evaluated for Type 3 vWD.

Inadequate Owner Communication

Owners of dogs with vWD need clear guidance on recognizing bleeding signs, when to seek veterinary care, and which drugs to avoid. Failure to provide written instructions can lead to preventable bleeding episodes. Provide a laminated card or digital document summarizing the dog's condition, vWD type, and emergency contact information.

Welfare and Safety Context

Animal Welfare Implications

Untreated vWD can cause significant suffering from uncontrolled bleeding, anemia, and pain. Epistaxis, gingival bleeding, and gastrointestinal bleeding can lead to chronic blood loss and iron deficiency anemia. Severe bleeding after surgery or trauma can be life-threatening. Prompt diagnosis and appropriate management are essential for maintaining quality of life. The World Organisation for Animal Health provides standards for animal health and welfare that apply to the management of hereditary disorders in companion animals (Animal Health and Welfare, World Organisation for Animal Health, https://www.woah.org/en/what-we-do/animal-health-and-welfare).

Breeding Ethics

Breeding dogs with vWD perpetuates the disorder in the population. Responsible breeding practices include genetic testing of all breeding animals and avoiding carrier-to-carrier matings. For breeds with high prevalence, such as Doberman Pinschers, widespread testing and selective breeding can reduce the incidence of vWD over time. Veterinarians have a responsibility to counsel breeders on the ethical implications of breeding affected or carrier dogs.

Safety Considerations for Treatment

Blood product administration carries risks, including transfusion reactions, volume overload, and infectious disease transmission. Cryoprecipitate and FFP should be obtained from reputable sources with screening protocols. DDAVP can cause hyponatremia and fluid retention, particularly in dogs with underlying renal or cardiac disease. Monitor electrolytes and urine output when using DDAVP, especially with repeated doses.

Regulatory Context

There are no specific regulations governing the diagnosis and management of vWD in dogs, but standard veterinary practice standards apply. Blood products must be handled according to established guidelines for storage, thawing, and administration. Genetic testing should be performed by accredited laboratories. The ACVIM provides consensus statements and guidelines for the diagnosis and management of hemostatic disorders in dogs and cats (ACVIM, https://www.acvim.org/).

Professional Escalation Criteria

Urgent Escalation

Immediate veterinary emergency care is required for any dog with uncontrolled bleeding, signs of hypovolemic shock, or suspected internal bleeding. Signs include pale mucous membranes, tachycardia, weak pulses, collapse, or abdominal distension. Dogs with severe epistaxis that does not respond to pressure, or with hematochezia or melena accompanied by weakness, require urgent evaluation. Administer intravenous fluids and blood products as needed, and refer to a specialty hospital if resources are limited.

Routine Escalation

Referral to a veterinary internal medicine specialist or a veterinary hematologist is indicated for dogs with suspected vWD that requires confirmation, for dogs with atypical presentations, or for cases where DDAVP response testing is needed. Dogs with Type 2 or Type 3 vWD should be managed in consultation with a specialist, especially for surgical planning. Breeders seeking genetic counseling should be referred to a specialist with expertise in hereditary coagulation disorders.

Diagnostic Escalation

If initial vWF:Ag testing is inconclusive or discordant with clinical signs, consider repeat testing or multimer analysis. Dogs with normal vWF:Ag but strong clinical suspicion for vWD may have a qualitative defect not detected by antigen assay. Refer to a coagulation laboratory for specialized testing. Dogs with concurrent thrombocytopenia or abnormal coagulation times should be evaluated for other hemostatic disorders before attributing bleeding to vWD.

Treatment Escalation

If a dog with known vWD experiences breakthrough bleeding despite prophylactic treatment, escalate to cryoprecipitate therapy if not already used. For dogs with Type 1 vWD that do not respond adequately to DDAVP, consider switching to cryoprecipitate for subsequent procedures. Dogs requiring repeated blood product transfusions should be monitored for transfusion reactions and alloimmunization.

Practical Decision Framework for Perioperative Hemostatic Support in Canine von Willebrand Disease

Risk Stratification Algorithm

A structured decision framework for perioperative hemostatic support in dogs with von Willebrand disease requires systematic risk stratification based on three core variables: vWD type, vWF:Ag level, and surgical procedure category. The Merck Veterinary Manual provides reference information on canine coagulation disorders and their perioperative management considerations (Merck Veterinary Manual, https://www.merckvetmanual.com/). Begin by classifying the surgical procedure into one of three risk categories. Low-risk procedures include routine dental cleaning without extractions, nail trimming, minor laceration repair, and cystotomy. Moderate-risk procedures include ovariohysterectomy, castration, fracture repair, and dental extractions. High-risk procedures include major orthopedic surgery, thoracotomy, splenectomy, and any surgery involving highly vascular tissues such as the nasal cavity or oral cavity with extensive dissection.

For each dog, assign a hemostatic risk score by combining the vWD type with the surgical category. Type 1 vWD with vWF:Ag above 50% of normal carries low hemostatic risk for low and moderate procedures but moderate risk for high procedures. Type 1 vWD with vWF:Ag between 30% and 50% carries moderate risk for low procedures and high risk for moderate and high procedures. Type 2 vWD carries high risk for all surgical categories due to the qualitative defect in high-molecular-weight multimers, even when vWF:Ag levels appear moderately reduced. Type 3 vWD carries the highest risk for all procedures, with vWF:Ag levels below 1% of normal and no endogenous vWF reserve to mobilize.

Decision Algorithm for Prophylactic Treatment Selection

The selection of prophylactic treatment follows a stepwise algorithm based on risk stratification and vWD type. For low-risk procedures in Type 1 dogs with vWF:Ag above 50%, no prophylactic treatment is required. Monitor the dog closely during and after the procedure, and have cryoprecipitate available for rescue if unexpected bleeding occurs. For low-risk procedures in Type 1 dogs with vWF:Ag between 30% and 50%, administer DDAVP at 1 microgram per kilogram subcutaneously 30 to 60 minutes before the procedure. Assess the response by measuring vWF:Ag levels before and after DDAVP administration if possible. For moderate-risk procedures in Type 1 dogs with vWF:Ag above 50%, administer DDAVP preoperatively. For moderate-risk procedures in Type 1 dogs with vWF:Ag between 30% and 50%, administer DDAVP and have cryoprecipitate available for rescue. For high-risk procedures in Type 1 dogs regardless of vWF:Ag level, administer cryoprecipitate preoperatively. For all procedures in Type 2 and Type 3 dogs, administer cryoprecipitate preoperatively. DDAVP is not effective in Type 3 vWD because there is no stored vWF to release, and its efficacy in Type 2 vWD is variable and unreliable.

DDAVP Response Testing Protocol

Before using DDAVP for perioperative prophylaxis in a dog with Type 1 vWD, perform a DDAVP response test to confirm adequate vWF release. This test should be conducted at least one week before the scheduled procedure. Collect a baseline plasma sample for vWF:Ag measurement. Administer DDAVP at 1 microgram per kilogram subcutaneously. Collect a second plasma sample 60 minutes after DDAVP administration. Measure vWF:Ag in both samples. A successful response is defined as an increase in vWF:Ag to at least 50% of normal or a doubling of the baseline level. If the response is inadequate, plan to use cryoprecipitate for the procedure instead of DDAVP. Document the response test results in the dog's medical record for future reference. The ACVIM provides resources on hemostatic testing protocols and interpretation of coagulation test results (ACVIM, https://www.acvim.org/).

Cryoprecipitate Dosing and Administration Protocol

Cryoprecipitate dosing for dogs with vWD is based on the severity of the deficiency and the anticipated blood loss. A standard dose is 1 unit of cryoprecipitate per 10 kilograms of body weight, administered intravenously over 30 to 60 minutes. For severe cases or high-risk procedures, a higher dose of 1 unit per 5 kilograms may be needed. Thaw cryoprecipitate in a 37-degree Celsius water bath immediately before administration. Do not refreeze thawed cryoprecipitate. Administer through a standard blood administration set with a filter. Monitor the dog for signs of transfusion reaction, including urticaria, facial edema, vomiting, or dyspnea. If a reaction occurs, stop the infusion, administer diphenhydramine at 1 to 2 milligrams per kilogram intramuscularly or intravenously, and restart at a slower rate once signs resolve. Record the dose, administration rate, and any adverse reactions in the medical record.

Postoperative Monitoring Protocol

Postoperative monitoring for dogs with vWD requires a structured protocol to detect bleeding early and intervene promptly. Monitor the surgical site every 2 hours for the first 12 hours, then every 4 hours for the next 36 hours. Record the presence and severity of any bleeding, swelling, or discharge. Monitor mucous membrane color, capillary refill time, heart rate, and respiratory rate every 4 hours for the first 24 hours. Measure packed cell volume (PCV) and total solids at 6 hours and 24 hours postoperatively. A drop in PCV of more than 10% from preoperative values warrants investigation for occult bleeding. For dogs that received DDAVP, monitor serum sodium and urine output for 24 hours due to the risk of hyponatremia and fluid retention. For dogs that received cryoprecipitate, monitor for delayed transfusion reactions for 48 hours. Document all monitoring parameters in a standardized postoperative flow sheet.

Record System for Perioperative Management

Maintain a standardized perioperative record for each dog with vWD undergoing surgery. The record should include the following sections. Preoperative assessment: vWD type, vWF:Ag level, genetic test results if available, previous bleeding history, current medications, and surgical procedure category. Risk stratification: hemostatic risk score (low, moderate, high) and planned prophylactic treatment. DDAVP response test results if applicable: baseline vWF:Ag, post-DDAVP vWF:Ag, and response classification (adequate or inadequate). Intraoperative record: prophylactic treatment administered (product, dose, route, time), intraoperative bleeding assessment (mild, moderate, severe), estimated blood loss in milliliters, and any rescue treatments administered. Postoperative monitoring: PCV and total solids at 6 and 24 hours, bleeding assessment at each monitoring interval, any bleeding episodes with description and intervention, and any transfusion reactions or adverse events. Discharge instructions: activity restrictions, medications to avoid, signs of bleeding to monitor, and emergency contact information. This record system allows for continuous quality improvement and provides a reference for future surgical planning.

Common Failure Patterns in Perioperative Management

Failure to perform DDAVP response testing before surgery is a common error. Without response testing, the clinician cannot predict whether DDAVP will be effective, leading to inadequate hemostatic support during the procedure. Always perform response testing at least one week before the scheduled surgery. Another failure pattern is using DDAVP in Type 3 vWD, where it is ineffective because there is no stored vWF to release. Confirm the vWD type before selecting prophylactic treatment. Inadequate cryoprecipitate dosing is another frequent problem. Underdosing fails to raise vWF:Ag to hemostatic levels, while overdosing increases the risk of volume overload and transfusion reactions. Use weight-based dosing and adjust based on the severity of the deficiency and the surgical risk. Failure to monitor postoperative bleeding adequately can lead to delayed recognition of hemorrhage. Implement a structured monitoring protocol with defined intervals and parameters. Finally, failing to document the perioperative plan and results in the medical record compromises continuity of care and future surgical planning. Maintain complete records for every dog with vWD undergoing surgery.

Welfare and Safety Context for Perioperative Management

The welfare implications of inadequate perioperative hemostatic support are significant. Uncontrolled surgical bleeding causes pain, anemia, prolonged recovery, and in severe cases, death. Dogs with vWD that experience a bleeding complication during surgery may require emergency transfusion, additional surgical intervention, and extended hospitalization. The World Organisation for Animal Health provides standards for animal health and welfare that apply to the management of hereditary disorders in companion animals, emphasizing the importance of preventive care and risk mitigation (Animal Health and Welfare, World Organisation for Animal Health, https://www.woah.org/en/what-we-do/animal-health-and-welfare). Safety considerations for blood product administration include the risk of transfusion reactions, volume overload, and infectious disease transmission. Obtain cryoprecipitate from reputable sources with donor screening protocols. Monitor dogs receiving DDAVP for hyponatremia, particularly those with underlying renal or cardiac disease. The ACVIM provides consensus statements on transfusion medicine and hemostatic management in dogs and cats (ACVIM, https://www.acvim.org/).

Professional Escalation Criteria for Perioperative Bleeding

Immediate escalation to emergency care is required for any dog with uncontrolled surgical bleeding, signs of hypovolemic shock, or suspected internal hemorrhage. Signs include pale mucous membranes, tachycardia, weak pulses, hypotension, or abdominal distension. Administer intravenous crystalloids at shock doses, obtain blood for crossmatching, and administer cryoprecipitate or fresh frozen plasma if available. Refer to a specialty hospital with 24-hour critical care capabilities if resources are limited. Routine escalation to a veterinary internal medicine specialist or veterinary hematologist is indicated for dogs with vWD that require complex surgical planning, for dogs with atypical bleeding patterns, or for cases where DDAVP response testing is inconclusive. Dogs with Type 2 or Type 3 vWD should be managed in consultation with a specialist for all surgical procedures. Diagnostic escalation is indicated when postoperative bleeding occurs despite appropriate prophylactic treatment. Repeat vWF:Ag testing, consider multimer analysis if not already performed, and evaluate for concurrent hemostatic disorders such as thrombocytopenia or coagulation factor deficiencies. Treatment escalation is indicated when a dog with known vWD experiences breakthrough bleeding despite prophylactic treatment. Switch from DDAVP to cryoprecipitate if not already used, increase the cryoprecipitate dose, and consider adjunctive treatments such as tranexamic acid or aminocaproic acid under specialist guidance. Document all escalation decisions and outcomes in the medical record for future reference.

Frequently Asked Questions

What are the most common symptoms of von Willebrand disease in dogs?

The most common symptoms include epistaxis, gingival bleeding, prolonged bleeding from nail trims, hematuria, and excessive bleeding after surgery or trauma. Petechiae and ecchymoses may be present but are less common. Gastrointestinal bleeding can cause melena or hematochezia. The severity of symptoms varies with the type and degree of vWF deficiency, with Type 3 dogs showing the most severe bleeding tendencies.

How is von Willebrand disease diagnosed in dogs?

Diagnosis begins with a thorough history and physical examination, followed by a CBC to rule out thrombocytopenia. Buccal mucosal bleeding time is a screening test for primary hemostatic function. The diagnostic test is measurement of plasma vWF antigen concentration (vWF:Ag). Genetic testing is available for breeds with known mutations. Multimer analysis may be needed to distinguish Type 2 from Type 1 vWD.

Which dog breeds are most commonly affected by von Willebrand disease?

Doberman Pinschers have a high carrier rate for Type 1 vWD. Scottish Terriers are predisposed to Type 3 vWD, the most severe form. Shetland Sheepdogs, German Shepherds, and German Shorthaired Pointers also show increased prevalence. Other affected breeds include Chesapeake Bay Retrievers, Dutch Kooikers, and Pembroke Welsh Corgis. Breed-specific mutations have been identified for several of these breeds.

Can von Willebrand disease be cured in dogs?

There is no cure for vWD, as it is a hereditary disorder. Management focuses on preventing and controlling bleeding episodes. Perioperative prophylaxis with cryoprecipitate or DDAVP can reduce surgical bleeding risk. Avoidance of antiplatelet drugs and careful surgical planning are essential. Genetic testing and selective breeding can reduce the incidence of vWD in affected breeds.

What is the difference between Type 1, Type 2, and Type 3 von Willebrand disease?

Type 1 vWD is a partial quantitative deficiency of vWF, with levels typically 30-60% of normal. Clinical signs are mild to moderate. Type 2 vWD is a qualitative defect with abnormal vWF multimers, causing moderate to severe bleeding. Type 3 vWD is a severe quantitative deficiency with near absent vWF, causing severe bleeding. Type 3 is most common in Scottish Terriers and Shetland Sheepdogs.

How is von Willebrand disease managed during surgery in dogs?

Management depends on the vWD type and surgical risk. For Type 1 dogs with mild deficiency and low-risk procedures, no prophylaxis may be needed. For moderate to severe cases, DDAVP can be used to stimulate vWF release in Type 1 dogs. Cryoprecipitate is the treatment of choice for Type 2 and Type 3 vWD. Fresh frozen plasma is an alternative when cryoprecipitate is unavailable. Avoid NSAIDs and other antiplatelet drugs perioperatively.

Is von Willebrand disease painful for dogs?

The disease itself is not painful, but bleeding episodes can cause discomfort. Epistaxis may cause irritation and difficulty breathing. Gastrointestinal bleeding can cause abdominal pain and nausea. Joint bleeds are uncommon in vWD but can occur with severe deficiency. Chronic blood loss can lead to anemia, causing weakness and lethargy. Prompt treatment of bleeding episodes improves comfort and quality of life.

Can dogs with von Willebrand disease live a normal life?

Many dogs with mild to moderate vWD can live a normal life with appropriate management. Avoiding trauma, using caution with nail trims and dental procedures, and avoiding antiplatelet drugs are important. Severe Type 3 dogs require more intensive management and may have a reduced quality of life due to spontaneous bleeding episodes. With proper veterinary care and owner education, most dogs with vWD can have a good quality of life.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Dog Kidney Disease Diet
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Platelet function in dogs with chronic liver disease.. The Journal of small animal practice, 2022.
• von Willebrand's disease in the dog and cat.. The Veterinary clinics of North America. Small animal practice, 1996.
• Prevalence of von Willebrand disease in dogs from Sao Paulo State, Brazil.. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 2010.
• Mouse models of von Willebrand disease.. Journal of thrombosis and haemostasis : JTH, 2009.
• Insights from von Willebrand disease animal models.. Cellular and molecular life sciences : CMLS, 1999.
• Von Willebrand's disease.. Progress in hemostasis and thrombosis, 1976.
• Von Willebrand disease in dogs. Medycyna Weterynaryjna, 1999.
• von Willebrand's disease. Comparative Haematology International, 1997.
• von Willebrand's disease. Comparative Clinical Pathology, 1997.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.